Abstract Concentrations of one or more carbohydrates phosphorylated at a secondary hydroxyl, including fructose-3-phosphate and sorbitol-3-phosphate, in biological tissue or cells of diabetic patients are determined by 31P NMR Spectroscopy, High Performance Liquid Chromatography (HPLC) or other appropriate analytical techniques. Elevated levels of such phosphorylated carbohydrates, relative to a prescribed standard or threshold level, are associated with an increased risk for developing the degenerative complications of diabetes. A method is provided for determining the relative concentrations of such phosphorylated carbohydrates, whereby the relative risk of a patient for the development of diabetic complications and the efficacy of therapeutic intervention in prevention of such complications may be assessed.
A method for assessing a diabetic patient's relative risk of experiencing a diabetes-associated pathologic condition, said method comprising the steps of: (a) measuring the levels of (i) a first compound, characterized by having a 31 P NMR shift of 6.63 at pH 7.5, an 1 H- 31 P coupling of 9.5 Hz and a pKa of 5.5, (ii) a second compound, characterized by having a 31 P NMR shift of 6.74 at pH 7.5, an 1 H- 31 P coupling of 9.5 Hz and a pKa of 5.5, and (iii) sorbitol-3-phosphate in said patient's red blood cells; (b) comparing the sum of said levels of measured first and second compounds to said level of measured sorbitol-3-phosphate; and (c) determining on the basis of said comparison whether said diabetic patient has an increased or a decreased risk of experiencing said diabetes-associated pathologic condition.
Claim 2
Independent Claim
142 words
A method for assessing a diabetic patient's relative risk of experiencing a diabetes-associated pathologic condition, said method comprising the steps of: (a) measuring the levels of (i) a first compound, characterized by having a 31 P NMR shift of 6.63 at pH 7.5, an 1 H- 31 P coupling of 9.5 Hz and a pKa of 5.5, (ii) a second compound, characterized by having a 31 P NMR shift of 6.74 at pH 7.5, an 1 H- 31 P coupling of 9.5 Hz and a pKa of 5.5, and (iii) sorbitol-3-phosphate in said patient's red blood cells; (b) comparing the sum of said levels of measured first and second compounds to said level of measured sorbitol-3-phosphate; and (c) determining on the basis of said comparison whether said diabetic patient has an increased or a decreased risk of experiencing said diabetes-associated pathologic condition.